Abstract: The present invention relates to the treatment of multiple myeloma in a human subject comprising administering lenadlidomide in combination with a vector which expresses a human eIF-SAI which is unable to be hypusinated and an siRNA which targets eIF-SAI. In some embodiments, the lenalidomide is administered simultaneously with the vector and the siRNA while in some embodiments the lenalidomide is administered at a time that is different from when the vector and the siRNA are administered. In some embodiments, the lenalidomide is administered orally and the vector and the siRNA are administered intraveneously.

Abstract: The present invention relates to the combinatorial use of an siRNA targeted against an endogenous gene to knock out or knock down expression of the endogenous gene in a host and a delivery of a polynucleotide encoding the gene in a delivery vehicle/expression vector to the host to provide expression in the host of the protein encoded by the polynucleotide.

Abstract: The present invention relates to the combinatorial use of an siRNA targeted against an endogenous gene to knock out or knock down expression of the endogenous gene in a host and a delivery of a polynucleotide encoding the gene in a delivery vehicle/expression vector to the host to provide expression in the host of the protein encoded by the polynucleotide.

Abstract: The present invention relates to the combinatorial use of an siRNA targeted against an endogenous gene to knock out or knock down expression of the endogenous gene in a host and a delivery of a polynucleotide encoding the gene in a delivery vehicle/expression vector to the host to provide expression in the host of the protein encoded by the polynucleotide.

Abstract: The present invention concerns compositions comprising an IL-1 mutein that is useful as an adjuvant for stimulating a controlled immune response when administered to a human or animal. For example, muteins of IL-1&bgr; can be used according to the invention. The mutein composition can include a vaccine antigen, such as whole inactivated or attenuated virus, recombinant or synthetic peptides, and other antigenic materials.

Abstract: The present invention concerns compositions comprising an IL-1 mutein that is useful as an adjuvant for stimulating a controlled immune response when administered to a human or animal. For example, muteins of IL-1&bgr; can be used according to the invention. The mutein composition can include a vaccine antigen, such as whole inactivated or attenuated virus, recombinant or synthetic peptides, and other antigenic materials. The present invention also pertains to the use of an IL-1 mutein in a human or animal as an adjuvant to increase immune responses to an antigen or other material to which an immune response is desired.

Abstract: The present invention concerns compositions comprising an IL-1 mutein that is useful as an adjuvant for stimulating a controlled immune response when administered to a human or animal. For example, muteins of IL-1&bgr; can be used according to the invention. The mutein composition can include a vaccine antigen, such as whole inactivated or attenuated virus, recombinant or synthetic peptides, and other antigenic materials.

Abstract: A new immunoassay system is provided for the detection of ligands or ligand binding partners in solution in a heterogeneous format. The invention relies upon the detection of back scattered light from an evanescent wave disturbed by the presence of a colloidal gold label brought to the interface by an immunological reaction. The evanescent wave existing at the interface in turn is the result of a totally internally reflected incident light wave. Placement of the detector at a back angle above the critical angle insures a superior signal-to-noise ratio.